Achieve fast and viable uptake of iron with Ferinject.
After 30 minutes: Rapid uptake of Ferinject without saturating transport systems to the bone marrow. 1
In patients with inflammatory bowel disease
In an RCT patients receiving Ferinject by simplified dosing achieved a fast and sustained improvement in iron studies from week 1 and haemoglobin from week 2, compared to patients receiving Venofer▼(iron sucrose) by Ganzoni dosing (p<0.001)2
Ferinject was the only intravenous iron to demonstrate significantly superior efficacy compared with oral iron [OR = 1.9 with 95% CrI: (1.1; 3.2)] in a network meta-analysis. 3
In patients with heart failure
Ferinject is the only IV iron named by ESC and SIGN guidelines for the management of heart failure. 4,5
Ferinject demonstrated a beneficial effect on peak V02 in patients with CHF and iron deficiency and was successful in the correction of iron deficiency, compared to standard of care.6
Ferinject was associated with a reduced risk of first hospitalisation due to worsening heart failure vs placebo (HR: 0.39, 95% CI: 0.19-0.82, p=0.009).7
In patients with non-dialysis chronic kidney disease
Ferinject sustainably corrected iron parameters in line with KDIGO guidelines.8,9
Targeting 400–600 μg/L serum ferritin with Ferinject, significantly improved ferritin and TSAT levels vs oral iron within 4 weeks with just 1g Ferinject.8
Targeting higher ferritin levels with Ferinject allowed a quick and sustainable correction of anaemia.8
Hb significantly increased within 4 weeks vs oral iron group and was controlled over 1 year with only an average of four injections vs daily oral iron therapy.8
In patients with preoperative iron deficiency anaemia
Ferinject treatment in patients with colon cancer and anaemia undergoing elective surgery compared with no IV iron was associated with:10
- reduced length of hospitalisation
- decreased peri- and postoperative allogeneic RBC transfusion
- no signs of iron deficiency anaemia at 30 days post-surgery
Confidence from a breadth and depth of evidence11
- Beshara S et al. Brit J Haematol. 2003; 120: 853-859.
- Evstatiev R et al. Gastroenterology. 2011; 141: 846-853.
- Aksan A et al. Aliment Pharmacol Ther 2017; 45: 1303-1318.
- Ponikowski P et al. Eur Heart J 2016; 37: 2129-2200.
- Scottish Intercollegiate Guidelines Network: SIGN 147: Management of chronic heart failure: A national guideline. March 2016, http://sign.ac.uk/pdf/SIGN147.pdf (Last accessed August 2018).
- Van Veldhuisen DJ et al. Circulation. 2017; 136: 1374-1383.
- Ponikowski P et al. Eur Heart J. 2015; 36(11): 657-668.
- Macdougall IC et al. Nephrol Dial Transplant 2014;29: 2075-2084.
- KDIGO. Kidney Int Suppl 2012; 2: 279-335.
- Calleja JL et al. Int J Colorectal Dis. 2016;31:543–551.
- Vifor Pharma Data on file 118.